• Home
  • Who We Are
  • News
  • For Patients
  • Technology
  • Investors
  • Contact Us
  • Development Program
  • Stem Cell Research in AMD
  • More
    • Home
    • Who We Are
    • News
    • For Patients
    • Technology
    • Investors
    • Contact Us
    • Development Program
    • Stem Cell Research in AMD
  • Home
  • Who We Are
  • News
  • For Patients
  • Technology
  • Investors
  • Contact Us
  • Development Program
  • Stem Cell Research in AMD

Highlights from the Podium and In the News

THE STEM CELLAR Sometimes a cold stare is a good thing

THE STEM CELLAR Sometimes a cold stare is a good thing

THE STEM CELLAR Sometimes a cold stare is a good thing

Read the latest blog post (or listen on Spotify) profiling our program on  THE STEM CELLAR, The Official Blog of CIRM, California's Stem Cell Agency.



Read the full post here

University of California Santa Barbara - The Current

THE STEM CELLAR Sometimes a cold stare is a good thing

THE STEM CELLAR Sometimes a cold stare is a good thing

In an article for UCSB - The Current, Britney Pennington and Lincoln Johnson discuss how novel cryopreservation methods enable long-term storage and worldwide distribution of a cellular therapy for age-related macular degeneration. 

Read the full article here

Publication in Scientific Reports

THE STEM CELLAR Sometimes a cold stare is a good thing

Publication in Science and Translational Medicine

  In a paper published in the journal Scientific Reports, RPT scientists in collaboration with colleagues at the University of California Santa Barbara and the University of Southern California report a novel cryopreservation technique that facilitates long-term storage of RPT’s CPCB-RPE1 ocular implants. This technique will greatly enhance the ability to widely distribute the implants and increase the number AMD patients that are able to receive the treatment. 

Read the full article here

Publication in Science and Translational Medicine

Publication in Science and Translational Medicine

Publication in Science and Translational Medicine

Publication of preliminary results from our Phase 1/2a clinical trial in dry age-related macular degeneration - The cover story in Science Translational Medicine  

Read more

AARP - Medical Breakthroughs of 2020

Publication in Science and Translational Medicine

AARP - Medical Breakthroughs of 2020

AARP highlights RPT Study participant in:   Saving Their Health and Ours.  Medical Breakthroughs of 2020

Read more

First Step

Publication in Science and Translational Medicine

AARP - Medical Breakthroughs of 2020

A video produced by the Roski Eye Institute - highlighting the first implant procedure

Click to Watch

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

A participant in our clinical trial shares her story.

Click to Watch

Vision for the Future: Stem Cell Therapy for Eye Disease

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

RPT co-founder Dr. Dennis Clegg describes the recent strategies to develop a regenerative patch for the treatment of age-related macular degeneration by developing a cellular therapy using stem cells. 

Click to watch

TEDx talk - Stemming Vision Loss with Stem Cells

Hope is in Sight for Dry AMD: First-in-Kind Stem Cell-Based Retinal Implant

TEDx talk - Stemming Vision Loss with Stem Cells

TEDx talk - Stemming Vision Loss with Stem Cells-  RPT co-founder Dr. Dennis Clegg    


Find out more

Featured in National Geographic

Featured in National Geographic

TEDx talk - Stemming Vision Loss with Stem Cells

Why There’s New Hope About Ending Blindness  

Find out more

The Story of Sight

Featured in National Geographic

The Story of Sight

Highlighted in the documentary Story of Sight 

Click to see a preview

From the Podium

Development of a Bio-Engineered Implant for AMD Treatment

 Dr. Jane Lebkowski shares her presentation from the virtual 2020 Cell & Gene Meeting on the Mesa, describing RPTs program and development our bio-engineered implant for the treatment of AMD  

Download PDF

publications

Xeno-free cryopreservation of adherent retinal pigmented epithelium yields viable and functional cells in vitro and in vivo.  

Pennington BO, Bailey JK,  Faynus MA, Hinman C, Hee MN, Ritts R, Nadar V, Zhu D, Mitra D,  Martinez-Camarillo JC, Lin TC, Thomas BB, Hinton DR, Humayun MS,  Lebkowski J, Johnson LV, Clegg DO. Sci Rep. 2021 Mar 18;11(1):6286. 


Surgical  Method for Implantation of a Biosynthetic Retinal Pigment Epithelium  Monolayer for Geographic Atrophy: Experience from a Phase 1/2a Study.

Kashani AH, Uang J, Mert M, Rahhal F, Chan C, Avery RL, Dugel P, Chen S, Lebkowski J, Clegg DO, Hinton DR, Humayun MS. Ophthalmol Retina. 2020 Mar;4(3):264-273. 


Subretinal Implantation of a Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Monolayer in a Porcine Model.

Kashani AH, Martynova A, Koss M, Brant R, Zhu DH, Lebkowski J, Hinton D, Clegg D, Humayun MS.

Adv Exp Med Biol. 2019;1185:569-574. 


A Bioengineered Retinal Pigment Epithelial Monolayer for Advanced, Dry Age-Related Macular Degeneration.

Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, Lin CM, Mitra D, Zhu D,  Thomas BB, Hikita ST, Pennington BO, Johnson LV, Clegg DO, Hinton DR, Humayun MS. Sci Transl Med. 2018 Apr 4;10(435). pii: eaao4097. 

Copyright © 2018 Regenerative Patch Technologies, LLC - All Rights Reserved.